β-Lactamase-dependent prodrugs - Recent developments

Tetrahedron

Volumn 56, Issue 31, 2000, Pages 5699-5707

  Smyth, Timothy P ^a   O'Donnell, Michael E ^a   O'Connor, Michael J ^a   St Ledger, James O ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Antibody directed enzyme prodrug therapy; NMR; Lactam

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; PRODRUG;

CHEMICAL ANALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONFERENCE PAPER; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 0034725844     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(00)00419-1     Document Type: Conference Paper

References (71)

1. (a) Matagne, A.; Dubus, A.; Galleni, M.; Frère, J.-M. Nat. Prod. Rep. 1999, 16, 1-19.
2. (b) Kotra, L. P.; Mobashery, S. Bull. Inst. Pasteur 1998, 96, 139-150.
3. (c) Pitout J. D. D.; Sanders, C. C.; Sanders, W. E. Am. J. Med. 1997, 103, 51-59.
4. For leading references see: (a) Svensson, H. P.; Frank, I. S.; Berry, K. K.; Senter, P. D. J. Med. Chem. 1998, 41, 1507-1512 and references cited therein. (b) Bagshawe, K. D.; Begent, R. H. J. Adv. Drug Delivery Rev. 1996, 22, 365-367. (c) Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Antoniw, P. Tumour Targeting 1995, 1, 17-29. (d) Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Chem. Biol. 1995, 2, 223-227. (e) See also www.seattlegenetics.com/.
5. For leading references see: (a) Svensson, H. P.; Frank, I. S.; Berry, K. K.; Senter, P. D. J. Med. Chem. 1998, 41, 1507-1512 and references cited therein. (b) Bagshawe, K. D.; Begent, R. H. J. Adv. Drug Delivery Rev. 1996, 22, 365-367. (c) Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Antoniw, P. Tumour Targeting 1995, 1, 17-29. (d) Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Chem. Biol. 1995, 2, 223-227. (e) See also www.seattlegenetics.com/.
6. For leading references see: (a) Svensson, H. P.; Frank, I. S.; Berry, K. K.; Senter, P. D. J. Med. Chem. 1998, 41, 1507-1512 and references cited therein. (b) Bagshawe, K. D.; Begent, R. H. J. Adv. Drug Delivery Rev. 1996, 22, 365-367. (c) Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Antoniw, P. Tumour Targeting 1995, 1, 17-29. (d) Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Chem. Biol. 1995, 2, 223-227. (e) See also www.seattlegenetics.com/.
7. For leading references see: (a) Svensson, H. P.; Frank, I. S.; Berry, K. K.; Senter, P. D. J. Med. Chem. 1998, 41, 1507-1512 and references cited therein. (b) Bagshawe, K. D.; Begent, R. H. J. Adv. Drug Delivery Rev. 1996, 22, 365-367. (c) Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Antoniw, P. Tumour Targeting 1995, 1, 17-29. (d) Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Chem. Biol. 1995, 2, 223-227. (e) See also www.seattlegenetics.com/.
8. For leading references see: (a) Svensson, H. P.; Frank, I. S.; Berry, K. K.; Senter, P. D. J. Med. Chem. 1998, 41, 1507-1512 and references cited therein. (b) Bagshawe, K. D.; Begent, R. H. J. Adv. Drug Delivery Rev. 1996, 22, 365-367. (c) Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Antoniw, P. Tumour Targeting 1995, 1, 17-29. (d) Rodrigues, M. L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Blackburn, B. K. Chem. Biol. 1995, 2, 223-227. (e) See also www.seattlegenetics.com/.
9. Pratt R.F., Faraci W.S. J. Am. Chem. Soc. 108:1986;5328-5333.
10. Knowles J.R. Acc. Chem. Res. 18:1985;97-104.
11. (a) Albrecht, H. A.; Beskid, G.; Chan, K.-K.; Christenson, J. G.; Cleeland, R.; Deitcher, K. H.; Georgopapadakou, N. H.; Keith, D. D.; Pruess, D. L.; Sepinwall, J.; Specian, A. C.; Then, R. L.; Weigele, M.; West, K. F.; Yang, R. J. Med. Chem. 1990, 33, 77-86.
12. (b) Albrecht, H. A.; Beskid, G.; Christenson, J. G.; Durkin, J. W.; Fallat, V.; Georgopapadakou, N. H.; Keith, D. D.; Konzelmann, F. M.; Lipschitz, E. R.; McGarry, D. H.; Siebelist, J.-A.; Wei, C. C.; Weigele, M.; Yang, R. J. Med. Chem. 1991, 34, 669-675.
13. (c) Albrecht, H. A.; Beskid, G.; Christenson, J. G.; Georgopapaakou, N. H.; Keith, D. D.; Konzelmann, F. M.; Pruess, D. L.; Rossman, P. L.; Wei, C.-C. J. Med. Chem. 1991, 34, 2857-2864.
14. (d) Albrecht, H. A.; Beskid, G.; Christenson, J. G.; Dietcher, K. H.; Georgopapadakou, N. H.; Keith, D. D.; Konzelmann, F. M.; Pruess, D. L.; Wei, C. C. J. Med. Chem. 1994, 37, 400-407.
15. (e) Demuth, T. P.; White, R. E.; Tietjen, R. A.; Storrin, R. J.; Skuster, J. R.; Andersen, J. A.; McOsker, C. C.; Freedman, R.; Rourke, F. J. J. Antibiot. 1991, 44, 200-209.
16. (a) Corraz, A. J.; Dax, S. L.; Dunlap, N. K.; Georgeopapadakou, N. H.; Keith, D. D.; Pruess, D. L.; Rossman, P. L.; Then, R.; Unowsky, J.; Wei, C.-C. J. Med. Chem., 1992, 35, 1828-1839.
17. (b) Perrone, E.; Jabés, D.; Alpegiani, M.; Andreini, B. P.; Bruna, C. D.; Nero, S. D.; Rossi, R.; Visentin, G.; Zarini, F.; Franceschi, G. J. Antibiotics 1992, 45, 589-594.
18. (a) Smyth, T. P.; O'Donnell, M. E.; O'Connor, M. J.; St Ledger, J. O. J. Org. Chem. 1998, 63, 7600-7618.
19. (b) Smyth, T. P.; O'Connor, M. J.; O'Donnell, M. E. J. Org. Chem. 1999, 64, 3132-3138.
20. Gordon E.M., Chang H.W., Cimarusti C.M., Toeplitz B., Gougoutas J.Z. J. Am. Chem. Soc. 102:1980;1690-1702.
21. This is a well established diagnostic pattern in β-lactam chemistry, see: Davis, A. M.; Jones, M.; Page. M. I. J. Chem. Soc. Perkin Trans. 2, 1991, 1219-1223.
22. The value of 4.0 Å is taken from the crystal structure data on the penicillin compound bearing the sulfenimine sidechain (RSN=) which was prepared by Gordon and co-workers; see Ref 8.
23. Menger, F. M. Acc. Chem. Res. 1985, 18, 128-134; 1993, 26, 206-212.
24. Menger, F. M. Acc. Chem. Res. 1985, 18, 128-134; 1993, 26, 206-212.
25. (a) Bohme, H.; Sell, K. Chem. Ber. 1948, 81, 123-130.
26. (b) Bird, R.; Stirling, J. M. J. Chem. Soc., Perkin Trans. 2 1973, 1221-1226 and references therein.
27. (a) The reaction of piperidine-1-sulfenyl chloride with diamines to yield (cyclic) thiadiazoles provides a key intramolecular example: Bryce, M. R. J. Chem. Soc., Perkin Trans. 1 1984, 2591-2593.
28. 3) with primary and secondary amines is a relevant intermolecular example: Armitage, D. A.; Clark. M. J.; Kinsey, A. C. J. Chem. Soc. (C) 1971, 3867-3869.
29. (c) See also: Capozzi, C.; Modena, G.; Pasquato, L. In The Chemistry of Sulphenic Acids and Derivatives; Patai, S., Ed.; Wiley: Chichester, 1990, Chapter 10. Hogg, D. R. In The Chemistry of Sulphenic Acids and Derivatives; Patai, S., Ed.; Wiley: Chichester, 1990, Chapter 9.
30. (c) See also: Capozzi, C.; Modena, G.; Pasquato, L. In The Chemistry of Sulphenic Acids and Derivatives; Patai, S., Ed.; Wiley: Chichester, 1990, Chapter 10. Hogg, D. R. In The Chemistry of Sulphenic Acids and Derivatives; Patai, S., Ed.; Wiley: Chichester, 1990, Chapter 9.
31. (a) Supporting evidence for the interconversion of Inter-A and Inter-B is provided by the observed ready contraction of seven- and eight-membered cyclic sulfides to form fused bicyclic structures by the nucleophilic addition of the sulfur atom to a carbonium ion center: Cerè, V.; Peri, F.; Pollicino, S.; Antonio, A. J. Chem. Soc., Perkin Trans. 2 1998, 977-979. de Groot, A.; Boerma, J. A.; Wynberg, H. Tetrahedron Lett. 1968, 2365-2367.
32. (a) Supporting evidence for the interconversion of Inter-A and Inter-B is provided by the observed ready contraction of seven- and eight-membered cyclic sulfides to form fused bicyclic structures by the nucleophilic addition of the sulfur atom to a carbonium ion center: Cerè, V.; Peri, F.; Pollicino, S.; Antonio, A. J. Chem. Soc., Perkin Trans. 2 1998, 977-979. de Groot, A.; Boerma, J. A.; Wynberg, H. Tetrahedron Lett. 1968, 2365-2367.
33. (b) For other examples of the transannular interaction of a sulfur atom with a carbonium ion center see: Tabushi, I.; Tamaru, Y.; Yoshida, Z-I; Sugimoto, T. J. Am. Chem. Soc. 1975, 97, 2886-2891. Block, E. Reactions of Organosulfur Compounds; Academic Press: NY, 1978; Chapter 4.
34. (b) For other examples of the transannular interaction of a sulfur atom with a carbonium ion center see: Tabushi, I.; Tamaru, Y.; Yoshida, Z-I; Sugimoto, T. J. Am. Chem. Soc. 1975, 97, 2886-2891. Block, E. Reactions of Organosulfur Compounds; Academic Press: NY, 1978; Chapter 4.
35. A certain degree of enzyme inhibition also occurred with 4bm, however, the partition number in favour of turnover versus inhibition was 15 000; see Ref. 7a.
36. It is not clear that 6′ will be generated from 8′ (see below and also refer to Scheme 5) in aqueous buffer; it is probable that the end products result from further hydrolysis reactions of 8′. Products derived from reactions of sulfenic acids in aqueous solution are described in: Hogg, D. R.; Vipond, P.W. Int. J. Sulfur Chem. C 1971, 6, 17-22.
37. 3I with Proton Sponge.
38. Products derived from further hydrolytic reaction of an exo-methylene thiazine type structure, such as 16, are described in: Taibi-Tronche, P.; Massova, I.; Vakulenko, S. B.; Lerner, S. A.; Mobashery, S. J. Am. Chem. Soc. 1996, 118, 7441-7448.
39. (a) For details on β-lactamases as fully efficient enzymes see: Christensen, H.; Martin, M. T.; Waley, S. G. Biochem. J. 1990, 266, 853-861.
40. (b) For the seminal work on the classification of fully efficient enzymes see: Albery, W. J.; Knowles, J. R. Biochemistry 1976, 15, 5631-5640.
41. (c) Albery, W. J.; Knowles, J. R. Angew. Chem., Int. Ed. Engl. 1977, 16, 285-293.
42. (d) For details on the evolution of β-lactamases see: Knox, J. R.; Moews, P. C.; Frère, J.-M. Chem. Biol. 1996, 3, 937-947. Massova, I.; Mobashery, S. Antimicrob. Agents Chemother. 1998, 42, 1-17.
43. (d) For details on the evolution of β-lactamases see: Knox, J. R.; Moews, P. C.; Frère, J.-M. Chem. Biol. 1996, 3, 937-947. Massova, I.; Mobashery, S. Antimicrob. Agents Chemother. 1998, 42, 1-17.
44. (a) O'Callaghan, C. H.; Sykes, R. B.; Staniforth, S. E. Antimicrob. Agents Chemother. 1976, 245-248.
45. (b) Greenwood, D.; O'Grady, F. Antimicrob. Agents Chemother. 1976, 249-252.
46. Mobashery, S.; Johnson, M. J. Biol. Chem. 1986, 261, 7879-7887. Mobashery, S.; Johnson, M. Biochem. 1987, 26, 5878-5884.
47. Mobashery, S.; Johnson, M. J. Biol. Chem. 1986, 261, 7879-7887. Mobashery, S.; Johnson, M. Biochem. 1987, 26, 5878-5884.
48. (a) Beskid, G.; Siebelist, J.-A.; McGarry, C. M.; Cleeland, R.; Chan, K.; Keith, D. D. Chemother. 1990, 36, 109-116.
49. (b) Beskid, G.; Albrecht, H. A.; Fallat, V.; Keith, D. D.; Lipschitz, E. R.; McGarry, C. M.; McGarry, D. H.; Rossman, P.; Siebelist, J. Chemother. 1991, 37, 310-317.
50. Cars O. Diagn. Microbiol. Infect. Dis. 27:1997;29-33.
51. Christenson J.G., Chan K.K., Cleeland R., Dix-Holzknecht B., Farrish H.H., Patel I.H., Specian A. Antimicrob. Agents Chemother. 34:1990;1895-1900.
52. Gibson D.P., Ma X., Switzer A.G., Murphy V.A., Aardema M. J. Environ. Mol. Mutagen. 31:1998;345-351.
53. Chaïbi E.B., Sirot D., Paul G., Labia R. J. Antimicrob. Chemother. 43:1999;447-458.
54. A in streptogrammins (Barriere, J. C.; Paris, J. M. Drugs of the Future 1993, 18, 833-845), (ii) combination of trimethoprim with a sulfonamide, and (iii) combination of a β-lactamase inhibitor (e.g. clavulanic acid) with a transpeptidase inhibitor (e.g. amoxycillin).
55. (a) Berger, D.; Citarella, R.; Dutia, M.; Greenberger, L.; Hallett, W.; Paul, R.; Powell, D. J. Med. Chem. 1999, 42, 2145-2161.
56. (b) Kuin, A.; Aalders, M.; Lamfers, M.; van Zuidam, D. J.; Essers, M.; Beijnen, J. H.; Smets, L. A. Br. J. Cancer 1999, 79, 793-801.
57. (c) Teodori, E.; Dei, S.; Quidu, P.; Budriesi, R.; Chiarini, A.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Scapecchi, S. J. Med. Chem. 1999, 42, 1687-1697.
58. (d) Hiessböck, R.; Wolf, C.; Richter, E.; Hitzler, M.; Chiba, P.; Kratzel, M.; Ecker, G. J. Med. Chem. 1999, 42, 1921-1926.
59. (e) Griffin, R. J.; Srinivasan, S.; Bowman, K.; Calvert, A. H.; Curtin, N. J.; Newell, D. R.; Pemberton, L. C.; Golding, B. T. J. Med. Chem. 1998, 41, 5247-5256.
60. (f) Newlands, E. S.; Stevens, M. F. G.; Wedge, S. R.; Wheelhouse, R. T.; Brock, C. Cancer Treat. Rev. 1997, 23, 35-61.
61. (g) Bosch, I.; Croop, J. Biochem. Biophys. Acta 1996, 1288, F37-F54.
62. (h) Boulton, S.; Pemberton, L. C.; Porteous, J. K.; Curtin, N. J.; Griffin, R. J.; Golding, B. T.; Durkacz, B. W. Br. J. Cancer 1995, 72, 849-856.
63. (i) Fischel, J. L.; Barbé, V.; Berlion, M.; Formento, P.; Berrile, J.; Bizzari, J. P.; Milano, G. Eur. J. Cancer 1993, 29A, 2269-2273.
64. (j) McClay, E. F.; Albright, K. D.; Jones, J. A.; Christen, R. D.; Howell, S. B. Int. J. Cancer 1993, 55, 1018-1022.
65. (k) Morrow, C. S.; Cowan, K. H. Cancer Cells 1990, 2, 15-22.
66. (l) Gottesman, M. M.; Pastan, I. J. Clin. Oncol. 1989, 7, 409-411.
67. (a) Arnold, F. H. Acc. Chem. Res. 1998, 31, 125-131.
68. (b) Bornscheuer, W. T. Angew. Chem., Int. Ed. 1998, 37, 3105-3108.
69. For details on the successful application of directed evolution to the production of cephalosporinase enzymes with considerably enhanced activity towards designated β-lactams see: (c) Stemmer, W. P. C. Nature 1994, 370, 389-391. (d) Crameri, A.; Raillard, S.-A.; Bermudez, E.; Stemmer, W. P. C. Nature 1998, 391, 288-291. (e) See also www. maxygen.com/.
70. For details on the successful application of directed evolution to the production of cephalosporinase enzymes with considerably enhanced activity towards designated β-lactams see: (c) Stemmer, W. P. C. Nature 1994, 370, 389-391. (d) Crameri, A.; Raillard, S.-A.; Bermudez, E.; Stemmer, W. P. C. Nature 1998, 391, 288-291. (e) See also www. maxygen.com/.
71. For details on the successful application of directed evolution to the production of cephalosporinase enzymes with considerably enhanced activity towards designated β-lactams see: (c) Stemmer, W. P. C. Nature 1994, 370, 389-391. (d) Crameri, A.; Raillard, S.-A.; Bermudez, E.; Stemmer, W. P. C. Nature 1998, 391, 288-291. (e) See also www. maxygen.com/.